An AI-assisted morphoproteomic approach is a supportive tool in esophagitis-related precision medicine.

Journal: EMBO molecular medicine
PMID:

Abstract

Esophagitis is a frequent, but at the molecular level poorly characterized condition with diverse underlying etiologies and treatments. Correct diagnosis can be challenging due to partially overlapping histological features. By proteomic profiling of routine diagnostic FFPE biopsy specimens (n = 55) representing controls, Reflux- (GERD), Eosinophilic-(EoE), Crohn's-(CD), Herpes simplex (HSV) and Candida (CA)-esophagitis by LC-MS/MS (DIA), we identified distinct signatures and functional networks (e.g. mitochondrial translation (EoE), immunoproteasome, complement and coagulations system (CD), ribosomal biogenesis (GERD)), and pathogen-specific proteins for HSV and CA. Moreover, combining these signatures with histological parameters in a machine learning model achieved high diagnostic accuracy (100% training set, 93.8% test set), and supported diagnostic decisions in borderline/challenging cases. Applied to a young patient representing a use case, the external GERD diagnosis could be revised to CD and ICAM1 was identified as highly abundant therapeutic target. This resulted in CyclosporinA as a personalized treatment recommendation by the local multidisciplinary molecular inflammation board. Our integrated AI-assisted morphoproteomic approach allows deeper insights in disease-specific molecular alterations and represents a promising tool in esophagitis-related precision medicine.

Authors

  • Sven Mattern
    Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
  • Vanessa Hollfoth
    Department of Pathology and Neuropathology, University of Tübingen, Tübingen, Germany.
  • Eyyub Bag
    Department of Pathology and Neuropathology, University of Tübingen, Tübingen, Germany.
  • Arslan Ali
    Department of Pathology and Neuropathology, University of Tübingen, Tübingen, Germany.
  • Philip Riemenschneider
    University Cancer Center Frankfurt (UCT), University of Frankfurt, Frankfurt, Germany.
  • Mohamed A Jarboui
    Core Facility for Medical Proteomics, Institute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.
  • Karsten Boldt
    Core Facility for Medical Proteomics, Institute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.
  • Mihály Sulyok
    Institute for Pathology and Neuropathology, Eberhard Karls University, University Hospital of Tübingen , Tübingen 72076, Germany.
  • Anabel Dickemann
    Department of Pathology and Neuropathology, University of Tübingen, Tübingen, Germany.
  • Julia Luibrand
    Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
  • Stefano Fusco
  • Mirita Franz-Wachtel
    Proteome Center Tübingen, University of Tübingen, Tübingen, Germany.
  • Kerstin Singer
    Department of Pathology and Neuropathology, University of Tübingen, Tübingen, Germany.
  • Benjamin Goeppert
    Institute of Pathology and Neuropathology, Hospital RKH Kliniken Ludwigsburg, Ludwigsburg, Germany.
  • Oliver Schilling
    Institute for Surgical Pathology, Medical Center - University of Freiburg, 79106 Freiburg, Germany.
  • Nisar Malek
    Department of Internal Medicine I, University Hospital, University of Tübingen, Tübingen, Germany.
  • Falko Fend
    Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
  • Boris Macek
    Proteome Center Tübingen, University of Tübingen, Tübingen, Germany.
  • Marius Ueffing
    Department of Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
  • Stephan Singer
    Department of Pathology and Neuropathology, University of Tübingen, Tübingen, Germany. Stephan.Singer@med.uni-tuebingen.de.